Keywords: Human Genome Sciences, Fourth-quarter FY 2011/12 financial results, Benysta

GSK takeover target Human Genome sees 4th-qtr loss narrow

Article | 25 April 2012

Print This

Human Genome Sciences (Nasdaq: HGSI), the subject of a $2.59 billion hostile takeover bid from the UK’s GlaxoSmithKline (LSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in